Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Ann Hepatol ; 28(3): 101088, 2023.
Article in English | MEDLINE | ID: mdl-36933885

ABSTRACT

INTRODUCTION AND OBJECTIVES: Psychosocial stressors related to the coronavirus-19 (COVID-19) pandemic increased alcohol consumption. The effect on patients with alcohol-related liver diseases remains unclear. MATERIALS AND METHODS: Hospitalizations at a tertiary care center due to alcohol-related liver disease from March 1 through August 31 in 2019 (pre-pandemic cohort) and 2020 (pandemic cohort) were reviewed retrospectively. Differences in patient demographics, disease features, and outcomes were estimated in patients with alcoholic hepatitis utilizing T-tests, Mann-Whitney tests, Chi-square and Fisher Exact Tests and Anova models and logistic regression models in patients with alcoholic cirrhosis. RESULTS: 146 patients with alcoholic hepatitis and 305 patients with alcoholic cirrhosis were admitted during the pandemic compared to 75 and 396 in the pre-pandemic cohort. Despite similar median Maddrey Scores (41.20 vs. 37.45, p=0.57), patients were 25% less likely to receive steroids during the pandemic. Patients with alcoholic hepatitis admitted during the pandemic were more likely to have hepatic encephalopathy (0.13; 95% CI:0.01, 0.25), variceal hemorrhage (0.14; 95% CI:0.04, 0.25), require oxygen (0.11; 95% CI:0.01, 0.21), vasopressors (OR:3.49; 95% CI:1.27, 12.01) and hemodialysis (OR:3.70; 95% CI:1.22, 15.13). On average, patients with alcoholic cirrhosis had MELD-Na scores 3.77 points higher (95% CI:1.05, 13.46) as compared to the pre-pandemic and had higher odds of experiencing hepatic encephalopathy (OR:1.34; 95% CI:1.04, 1.73), spontaneous bacterial peritonitis (OR:1.88; 95% CI:1.03, 3.43), ascites (OR:1.40, 95% CI:1.10, 1.79), vasopressors (OR:1.68, 95% CI:1.14, 2.46) or inpatient mortality (OR:2.00, 95% CI:1.33, 2.99) than the pre-pandemic. CONCLUSIONS: Patients with alcohol-related liver disease experienced worse outcomes during the pandemic.


Subject(s)
COVID-19 , Esophageal and Gastric Varices , Hepatic Encephalopathy , Hepatitis, Alcoholic , Humans , Liver Cirrhosis, Alcoholic/epidemiology , Liver Cirrhosis, Alcoholic/therapy , Hepatic Encephalopathy/epidemiology , Pandemics , Hepatitis, Alcoholic/diagnosis , Hepatitis, Alcoholic/epidemiology , Retrospective Studies , Gastrointestinal Hemorrhage , Prognosis , COVID-19/epidemiology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/epidemiology
2.
Arch Gynecol Obstet ; 306(6): 1929-1937, 2022 12.
Article in English | MEDLINE | ID: mdl-35249153

ABSTRACT

BACKGROUND AND AIMS: Biologic agents have revolutionized treatment of immune mediated inflammatory diseases (IMIDs). However, despite the benefits of treatment, there is limited data on its use during pregnancy leading to significant variation in practices. We evaluated maternal, neonatal, and disease-related outcomes in pregnant women with IMIDs, comparing those with biologic exposure during pregnancy to those without exposure. Our hypothesis was that there would be no difference in outcomes between the two groups. METHODS: This is a retrospective cohort study conducted at a single tertiary care center including women with Crohn's disease (CD), ulcerative colitis (UC), ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PsA) who delivered between 2010 and 2018 at The Ohio State University Wexner Medical Center. Conditions were identified by ICD-9/ICD-10 code and confirmed by chart review. Demographic data, pregnancy outcomes and disease-related data were collected. RESULTS: There were 338 pregnancies including 100 with CD, 74 with UC, 15 with AS, 61 with RA, and 90 with PS/PsA. 23% of IMID patients had biologic exposure (biologic use within 3 months of conception) and 18% continued therapy during pregnancy. Those with biologic exposure had increased risk of post-partum disease flare (OR 3.44; 95% CI 1.29, 9.15) and were less likely to breastfeed (OR 0.44; 95% CI 0.23, 0.87). In subgroup analysis of patients with IBD, those with biologic exposure also had increased risk of post-partum flare (OR 4.55; 95% CI 1.27, 16.35). Maternal and neonatal pregnancy outcomes were similar. CONCLUSION: Among pregnant women with IMIDs, those that continued biologics during pregnancy had increased rates of major infection, disease related hospital admission, glucocorticoid use, and disease flare within 6 months post-partum, without any significant change in maternal or neonatal outcomes.


Subject(s)
Antirheumatic Agents , Arthritis, Psoriatic , Arthritis, Rheumatoid , Biological Products , Colitis, Ulcerative , Crohn Disease , Inflammatory Bowel Diseases , Spondylitis, Ankylosing , Infant, Newborn , Female , Humans , Pregnancy , Arthritis, Psoriatic/drug therapy , Pregnant Women , Retrospective Studies , Symptom Flare Up , Arthritis, Rheumatoid/drug therapy , Spondylitis, Ankylosing/drug therapy , Crohn Disease/drug therapy , Colitis, Ulcerative/drug therapy , Biological Products/adverse effects
3.
Am J Reprod Immunol ; 86(6): e13490, 2021 12.
Article in English | MEDLINE | ID: mdl-34358389

ABSTRACT

PROBLEM: Limited data exists on the temporal trend of the Sars-CoV-2 immunologic response and duration of protection following natural infection. We sought to investigate the presence and duration of Sars-CoV-2 serum antibodies in obstetrical healthcare workers (HCW) on serial assessments over a 6-month period, and to assess rates of vaccine acceptance and reported vaccine side effects among this cohort. METHOD OF STUDY: A prospective cohort study of a convenience sample of obstetrical HCWs at a tertiary hospital. Serum Sars-CoV-2 antibodies for Immunoglobulin G (IgG) and Immunoglobulin M (IgM) were measured longitudinally at four intervals: baseline, 4 weeks, 12 weeks, and 6 months. Participants completed voluntary surveys on COVID19 testing, high-risk exposures, vaccine acceptance, and vaccine side effects. RESULTS: One hundred twenty-six of 150 (84%) HCWs who volunteered for participation completed all four blood draws. Prevalence of seropositive HCWs based on positive Sars-CoV-2 IgG antibodies increased from 2% at baseline to 31% at 12 weeks but declined to 21% by 6 months. Forty-two percent (19/43) of the participants considered seropositive for Sars-CoV-2 IgG antibodies at any of the initial three blood draws converted to seronegative status at the 6-month follow-up. Eighty-seven percent (72/83) of participants who responded to a follow-up survey were willing to accept the COVID19 vaccine. Rates of acceptance did not differ by participant antibody status. Those that experienced symptoms with the first injection were more likely to have positive Sars-CoV-2 IgG antibodies (36.8% vs. 9.6%, p = .01). CONCLUSION: Sars-CoV-2 IgG antibodies wane over time and may not provide prolonged and robust immune protection. This underscores the importance of vaccination and continued research in this area while the COVID19 pandemic continues.


Subject(s)
Antibodies, Viral/blood , Health Personnel , Obstetrics , SARS-CoV-2/immunology , Adult , COVID-19/epidemiology , COVID-19 Testing , Follow-Up Studies , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Middle Aged , Prevalence , Prospective Studies , Seroepidemiologic Studies
4.
J Gastrointest Surg ; 24(1): 88-97, 2020 01.
Article in English | MEDLINE | ID: mdl-31432326

ABSTRACT

BACKGROUND: Surgery is common in patients with Crohn's disease and can contribute significantly to patient morbidity. The National Surgical Quality Improvement Program surgical risk calculator (NSQIP-SRC) that is currently utilized to predict surgical risk does not take Crohn's disease into account and, as a result, seems to underestimate risk in this patient population. This study aimed to evaluate the accuracy of the NSQIP-SRC in Crohn's disease patients and to evaluate the utility of disease severity scores in predicting surgical risk. METHODS: Between 2011 and 2017, there were 176 surgical cases involving Crohn's disease patients. Demographic data and 30-day surgical outcomes were collected. Disease severity scores including Harvey Bradshaw Index (HBI), Crohn's Disease Activity Index (CDAI), Simple Endoscopic Score for Crohn's Disease (SES-CD), and NSQIP-SRC risk percentages were calculated. RESULTS: Patients in remission based on HBI had a complication rate of 8.57% (n = 3), while those with mild or moderate-severe disease had rates of 33.33% (n = 11) and 38.46% (n = 20) respectively (p = 0.0045). In multivariable analysis, those with mild (OR; 8.37, 95% CI; 1.64, 42.78; p = 0.011) or moderate-severe (OR; 11.69, 95% CI; 2.42, 56.46; p = 0.002) disease had increased odds of complication compared to remission. Complication rate was not associated with NSQIP-SRC percent risk of any complication. CONCLUSION: NSQIP-SRC does not accurately predict risk in patients with CD undergoing surgery. Higher disease activity based on HBI is associated with increased odds of complication and may prove to be more predictive of surgical complication in the Crohn's patient population.


Subject(s)
Crohn Disease/surgery , Postoperative Complications/epidemiology , Adult , Aged , Aged, 80 and over , Crohn Disease/complications , Crohn Disease/pathology , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Sensitivity and Specificity , Severity of Illness Index
5.
J Homosex ; 59(9): 1289-306, 2012.
Article in English | MEDLINE | ID: mdl-23101498

ABSTRACT

Gay, lesbian, bisexual, transgender, and queer/questioning (GLBTQ) youth face oppression despite some increases in cultural support for GLBTQ individuals. Research has revealed the psychological and social distress associated with oppression and the benefits of peer social support programs. This study was conducted to analyze the types and frequency of services, age of participants, and organizational structures of the 116 GLBTQ community-based programs operating in the United States. Using an Internet survey, information from 61 of the programs was secured. The results revealed the community-based youth programs provide critical and unique programs and services that can promote the mental and physical health of GLBTQ youth.


Subject(s)
Bisexuality/psychology , Community Networks/organization & administration , Homophobia/psychology , Homosexuality, Female/psychology , Homosexuality, Male/psychology , Peer Group , Social Support , Social Welfare , Transgender Persons/psychology , Adolescent , Female , Humans , Male , Self-Help Groups/organization & administration , Social Identification , Socialization , United States , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...